Home » Health » CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful vigilantly but unsuccessfully to produce an one off therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire employment interview which I came away with an inadequate impression of the business.

Irony of irony, the bad opinion of mine of the company has grown steadily, although the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology and also connected intellectual property coming from Progenics to CytoDyn, as well as roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) and the very first new drug application approval ($5 million), as well as royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it has this individual therapies and a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple illness types, multiple presentations in addition to multiple publications.

Might all of it be smoke and mirrors? That is a question I’ve been asking myself through the very start of my interest in this company. Judging with the multiples of a huge number of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am much from alone in this question.

CytoDyn is a traditional battleground, or even some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News